Increased APOBEC3B predicts worse outcomes in lung cancer: A comprehensive retrospective study

Shumei Yan, Fan He, Bei Gao, Huini Wu, Mei Li, Liyun Huang, Jianzhong Liang, Qiuliang Wu, Yong Li

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Lung cancer ranks as the most common and lethal malignancy in America and worldwide. APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors. In this study, we combine the data of online databases and two hundred and twenty-one primary non-small-cell lung carcinoma (NSCLC) specimens from Sun Yat-sen University Cancer Center to investigate, for the first time, the clinical role of APOBEC3B in lung cancer. We found that the APOBEC3 expression was commonly elevated in NSCLC tissues and overexpression of APOBEC3B was correlated with unfavorable prognosis of the patients with NSCLC. Furthermore, APOBEC3B expression was associated with nodal status, TNM staging and adjuvant chemotherapy of the patients with NSCLC. Further research is warranted.

Original languageEnglish
Pages (from-to)618-625
Number of pages8
JournalJournal of Cancer
Volume7
Issue number6
DOIs
StatePublished - 2016

Keywords

  • APOBEC3B
  • Immunohistochemistry
  • Non-small-cell lung cancer
  • Prognosis

Fingerprint

Dive into the research topics of 'Increased APOBEC3B predicts worse outcomes in lung cancer: A comprehensive retrospective study'. Together they form a unique fingerprint.

Cite this